Welcome to our dedicated page for Progyny news (Ticker: PGNY), a resource for investors and traders seeking the latest updates and insights on Progyny stock.
Progyny, Inc. reports developments in women's health and family building benefits, including fertility care access, employer demand, product expansion, and financial results. The company provides benefit solutions for employers, health plans, and benefit purchasers, combining concierge support, coaching, education, digital tools, and access to a network of fertility and women's health specialists.
Recurring updates include quarterly earnings, financial guidance, selling-season activity, share repurchases, investor conference appearances, and offerings such as Progyny Select, a fully insured supplemental fertility and family building plan for small U.S. employers.
Progyny (Nasdaq: PGNY) announced that CFO Mark Livingston will participate in a fireside chat at the Jefferies Global Healthcare Conference on Tuesday, November 18, 2025 at 3:00 p.m. GMT / 10:00 a.m. ET.
A live audiocast and replay will be available from the Events and Presentations section of Progyny’s investor website at http://investors.progyny.com.
Progyny (Nasdaq: PGNY) reported 3Q 2025 revenue of $313.3M, up 9.3% year-over-year (or +23% excluding a large non-renewing client). The company posted gross profit $72.8M (+23%), net income $13.9M ($0.15 diluted) and Adjusted EBITDA $55.0M (+18%) with a 17.5% Adjusted EBITDA margin.
Key operational items include ~80 new clients adding ~900,000 lives, near 100% client retention for 2026, ~553 clients and average members ~6.76M. Cash flow was strong with $156.0M operating cash flow for the first nine months and cash & equivalents of $345.2M. The board authorized up to $200M for share repurchases and the company raised full-year 2025 guidance to revenue of $1.263B–$1.278B.
Progyny (Nasdaq: PGNY) will report financial results for the quarter ended September 30, 2025 after market close on Thursday, November 6, 2025.
The company will host a conference call at 4:45 P.M. ET / 1:45 P.M. PT the same day and will issue a press release before the call. U.S. dial-in: 1.866.825.7331 (passcode 265484); international dial-in: 1.973.413.6106. Audio replay available through Thursday, November 13, 2025. Live webcast and archive at http://investors.progyny.com.
Progyny provides employer-focused women’s health and family building benefits and is headquartered in New York City. For investor inquiries: investors@progyny.com.
Progyny (Nasdaq: PGNY) announced a global expansion of benefits to include pregnancy, postpartum, and menopause programs, available to employers starting January 1, 2026. The offerings complement Progyny’s existing global fertility and family building services to provide an integrated continuum across life stages.
Key features include personalized Global Care Advocates, a curated evidence-based knowledge center, country-specific navigator support, and a GDPR-compliant benefits platform. The program supports employees in more than 127 countries with multilingual capabilities.
Transcarent (PGNY) expanded its Experience Store on October 21, 2025 by adding three women’s health partners — Maven Clinic, Midi Health, and Progyny — to existing partners Carrot and Kindbody, aiming to centralize fertility, family-building, perimenopause and menopause care for Members.
The WayFinding™ generative-AI experience offers single sign-on, consolidated reporting, and measurable outcomes; Transcarent cites 7.6x more referrals to women’s health and a 10–20% increase in point-solution utilization when fragmentation is reduced.
Progyny (Nasdaq: PGNY) announced that CEO Pete Anevski was named a Champion for Women’s Health by the World Economic Forum and the Global Alliance for Women’s Health on October 7, 2025.
Anevski joins a global community of leaders committed to advocacy, policy, research, innovation, and investment to close care gaps in women’s health. Progyny said Chief Medical Officer Dr. Janet Choi also participated in GAWH workgroups on maternal health and women’s health science. The company said it will engage in Forum platforms and initiatives to promote research and scalable solutions across governments, investors, and industries worldwide.
Progyny (NASDAQ: PGNY), a women's health and family building solutions provider, reported strong Q2 2025 results with revenue of $332.9 million, up 9.5% year-over-year. Excluding a large transitioning client, revenue growth was 18%. The company achieved net income of $17.1 million ($0.19 per diluted share) and Adjusted EBITDA of $57.9 million.
Key metrics include 542 fertility clients (up from 463 YoY), 16,938 ART cycles performed, and 6.74 million average members. The company generated strong cash flow of $55.5 million in Q2 and a record $105.3 million in H1 2025.
Progyny raised its full-year 2025 guidance, projecting revenue of $1.235-1.270 billion (15.1-18.5% growth excluding the transitioning client) and net income of $52.3-58.9 million.
Progyny (Nasdaq: PGNY), a leader in women's health and family building solutions, released a national study revealing significant disparities in workplace health benefits. While 81% of HR leaders claim commitment to women's health, only 52% of working women find their benefits make healthcare affordable.
The research highlights critical gaps: while 83% of women prioritize menopause-related benefits, only 12% report adequate employer support. Additionally, 24% of women abandon using benefits due to complexity, and 83% of women and 88% of employers agree that centralized support would improve effectiveness. The study emphasizes the need for comprehensive women's health programs, as 69% of benefit managers consider these benefits crucial for attracting and retaining younger talent.
Progyny (Nasdaq: PGNY) has announced a strategic partnership with ŌURA, a leading smart ring manufacturer, to enhance women's health monitoring and care from preconception through menopause. The collaboration will integrate ŌURA's wearable technology data into Progyny's healthcare ecosystem starting in early 2026.
The partnership aims to provide comprehensive health tracking capabilities, including sleep patterns, cycle insights, cardiovascular health, and stress levels. This data integration will enable earlier risk identification and support various health goals, particularly in fertility planning and menopause management. The initiative will be available to Progyny's client base, including employers and health plans.
Progyny (NASDAQ: PGNY), a leader in women's health and family building solutions, has secured a new $200 million revolving credit facility maturing on July 1, 2030. The undrawn facility enhances the company's operational and financial flexibility, though there are no immediate plans for its use.
The company anticipates Q2 2025 financial results to exceed previous guidance due to favorable member activity. Revenue, Adjusted net income, and Adjusted EBITDA are expected to surpass the ranges provided in May. Progyny will report detailed Q2 2025 results on August 7, 2025, after market close.
The company maintains its capital priorities, including potential stock repurchases, product portfolio expansion, investments in distribution channels, and strategic acquisitions.